B. Riley Securities Reiterates Buy on MiNK Therapeutics, Raises Price Target to $50
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsReiterationPrice Target
B. Riley Securities analyst Mayank Mamtani reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and raises the price target from $43 to $50.
B. Riley Securities analyst Mayank Mamtani reiterates MiNK Therapeutics (NASDAQ:INKT) with a Buy and raises the price target from $43 to $50.